Bibliographic Info
GuidelineKey updates to the treatment of drug-resistant tuberculosis: rapid communication, June 2024.
Year of Publication2024
Issuing InstitutionWorld Health Organization
Recommendation
Status
Updated
Recommended in favor
Conditional
Certainty of evidence
Very low
WHO suggests the use of a 6-month treatment regimen composed of bedaquiline, delamanid, linezolid (600 mg), levofloxacin, and clofazimine (BDLLfxC) in MDR/RR-TB patients with or without fluoroquinolone resistance